BRISTOL-MYERS SQUIBB COMPANY

WORLDWIDE REVENUES

QUARTERLY REVENUES TREND ANALYSIS

(Unaudited, dollars in millions)

2019

2020

$ Change

% Change

1st Qtr

2nd Qtr

6 Months

3rd Qtr

9 Months

4th Qtr(b)

Year(b)

1st Qtr(c)

2nd Qtr

6 Months

3rd Qtr

9 Months

4th Qtr

Year

Qtr vs. Qtr

YTD vs. YTD

Qtr vs. Qtr

YTD vs. YTD

Prioritized Brands

Revlimid

$

-

$ -

$ -

$ -

$ -

$

1,299

$

1,299

$

2,915

$

2,915

$

2,915

N/A

N/A

Eliquis

1,925

2,042

3,967

1,928

5,895

2,034

7,929

2,641

716

716

37%

37%

Opdivo

1,801

1,823

3,624

1,817

5,441

1,763

7,204

1,766

(35)

(35)

(2)%

(2)%

Orencia

640

778

1,418

767

2,185

792

2,977

714

74

74

12%

12%

Pomalyst/Imnovid

-

-

-

-

-

322

322

713

713

713

N/A

N/A

Sprycel

459

544

1,003

558

1,561

549

2,110

521

62

62

14%

14%

Yervoy

384

367

751

353

1,104

385

1,489

396

12

12

3%

3%

Abraxane

-

-

-

-

-

166

166

300

300

300

N/A

N/A

Empliciti

83

91

174

89

263

94

357

97

14

14

17%

17%

Reblozyl

-

-

-

-

-

-

-

8

8

8

N/A

N/A

Inrebic

-

-

-

-

-

5

5

12

12

12

N/A

N/A

Established Brands

Baraclude

141

147

288

145

433

122

555

122

(19)

(19)

(13)%

(13)%

Vidaza

-

-

-

-

-

58

58

158

158

158

N/A

N/A

Other Brands(a)

487

481

968

350

1,318

356

1,674

418

(69)

(69)

(14)%

(14)%

Total

$

5,920

$

6,273

$

12,193

$

6,007

$

18,200

$

7,945

$

26,145

$

10,781

$

4,861

$

4,861

82%

82%

  1. Includes Sustiva, Reyataz, Daklinza and all other BMS and Celgene products acquired as part of the Celgene acquisition that have lost exclusivity in major markets,over-the-counter (OTC) brands and royalty revenue. Other Brands includes $122 million relating to Celgene products in the three months ended March 31, 2020.
  2. Includes Celgene product revenues from November 20, 2019 through December 31, 2019.
  3. Includes Celgene product revenues for the three months ended March 31, 2020.

Attachments

  • Original document
  • Permalink

Disclaimer

Bristol-Myers Squibb Company published this content on 07 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 May 2020 15:53:09 UTC